TrialArthritis research & therapy2023

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis.

Wolfgang A Schmidt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.